Sirolimus in Combination With MEC in High Risk Myeloid Leukemias

NCT00780104 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Myeloid Leukemias
AML
Leukemia
CML

Interventions

DRUG: Rapamycin, Mitoxantrone, Etoposide, Cytarabine
DRUG: Rapamycin + MEC

Sponsor

Abramson Cancer Center at Penn Medicine